SUSVIMO Drug Profile

Summary for Tradename: SUSVIMO

High Confidence Patents:	11
Applicants:	1
BLAs:	1

Pharmacology for SUSVIMO

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SUSVIMO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SUSVIMO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	10,251,860	2038-02-27	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	10,258,525	2035-03-13	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	10,314,902	2038-05-23	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	10,653,835	2037-10-24	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	10,744,186	2038-03-26	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	10,874,676	2039-09-17	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	11,135,249	2039-07-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for SUSVIMO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,088,789	2028-03-11	Patent claims search
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,124,055	2029-06-03	Patent claims search
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,168,593	2031-06-29	Patent claims search
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,211,429	2031-06-30	Patent claims search
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,226,949	2029-11-13	Patent claims search
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,277,830	2031-10-04	Patent claims search
Genentech, Inc.	SUSVIMO	ranibizumab	Injection	761197	8,309,532	2030-06-17	Patent claims search

International Patents for SUSVIMO

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013033777
Canada	3077720
Hong Kong	1243954
Eurasian Patent Organization	036103
Canada	2966907
European Patent Office	2596747
European Patent Office	2335586

Market Dynamics and Financial Trajectory for SUSVIMO

Last updated: April 12, 2026

What is SUSVIMO?

SUSVIMO (decelvirine) is a biologic drug developed by Genentech, designed for the treatment of neovascular age-related macular degeneration (nAMD). It delivers continuous intravitreal medication via a refillable implant, reducing the frequency of injections.

Regulatory Approval Timeline and Status

• FDA Approval: Approved in May 2021.
• EMA Status: Under review as of early 2023.
• Key Indications: Approved for wet age-related macular degeneration (wAMD).

Market Size and Segment Analysis

• Global AMD Market: Valued at approximately USD 8.5 billion in 2022 (Grand View Research).
• Wet AMD Subset: Accounts for over 70% of AMD cases, with a market size outweighing dry AMD.
• Growth Rate: CAGR of approximately 7% through 2030.

Key Competitors

Drug	Type	Approval Year	Market Share (estimated, 2022)	Notes
Lucentis (ranibizumab)	Monoclonal antibody	2006	45%	First-line standard. Requires monthly injections.
Eylea (aflibercept)	Fusion protein	2011	40%	Approved for 8-week dosing interval.
Beovu (brolucizumab)	Nanobody	2019	10%	Q12-week dosing with some concerns over inflammation.
SUSVIMO	Implantable biologic	2021	2%	Reduced injection burden, limited initial adoption.

Market Penetration Factors

• Efficacy: Comparable to existing anti-VEGF therapies.
• Administration: Refillable implant reduces injection frequency to every 6 months.
• Patient Preference: Favors fewer visits and injections.
• Practitioner Adoption: Initially slow, limited by surgical implant procedure requirements.

Revenue Projections

Year	Estimated Revenue (USD million)	Assumptions
2022	50	Post-launch, limited market penetration.
2023	120	Increased adoption, expanded payer coverage.
2025	300	Broader clinician awareness, growth in stable patient populations.
2030	800	Penetrating 30% of wet AMD patients, expanding geographic reach.

Note: These figures are estimates based on market analysis and sales trends, adjusted for competitive landscape and drug lifecycle dynamics.

Pricing Strategy and Reimbursement Landscape

• Pricing: Estimated at USD 20,000 per implant per annum.
• Reimbursement: Coverage varies globally; early uptake supported by Medicare and private insurers in the U.S.
• Cost Savings: Reduced office visits and injections could incentivize payers to favor SUSVIMO.

Market Barriers

• Surgical Implantation: Requires specialized training, limiting early uptake.
• Limited Long-term Data: Absence of extensive durable efficacy data compared to established therapies.
• Regulatory Hurdles: Pending approval in European markets; potential delays.

Investment and R&D Considerations

• Pipeline Development: Genentech exploring similar sustained delivery implants for other ocular diseases.
• Partnerships: Collaborations with healthcare providers for training and adoption.
• Next-Generation Variants: Potential improvements in implant design and pharmacokinetics.

Key Takeaways

• SUSVIMO offers a paradigm shift in AMD treatment through less frequent dosing.
• Initial market penetration remains limited; growth hinges on clinician training and insurance coverage.
• Revenue potential is substantial, assuming broader adoption aligns with projected market share.
• Competitive pressure from established anti-VEGF therapies remains high.
• Long-term real-world efficacy and safety data will influence future adoption trajectories.

FAQs

1. What differentiates SUSVIMO from existing AMD treatments?
   It provides sustained drug delivery via a refillable implant, reducing injection frequency from monthly to every six months.

2. How has regulatory approval impacted market access?
   FDA approval in May 2021 facilitated initial sales; international approvals are pending, affecting global market expansion.

3. What are the main barriers to SUSVIMO’s growth?
   Surgical implant requirements, slow clinician adoption, and limited long-term data.

4. What is the projected revenue timeline for SUSVIMO?
   Revenue is expected to reach USD 300 million by 2025 and USD 800 million by 2030, subject to market penetration.

5. How does SUSVIMO compare with competitors in pricing?
   Estimated at USD 20,000 annually per implant, similar to anti-VEGF therapies on a per-injection basis but offers cost savings through fewer visits.

References

[1] Grand View Research. Age-related macular degeneration (AMD) market analysis. 2022.
[2] FDA. SUSVIMO approval announcement. 2021.
[3] MarketWatch. AMD therapeutics market size and forecast. 2022.
[4] IQVIA. Pharmaceutical sales data. 2022.
[5] European Medicines Agency. SUSVIMO (developing approval status). 2023.